Analyst Price Targets — ARVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 18, 2026 3:18 pm | Srikripa Devarakonda | Truist Financial | $10.00 | $10.96 | StreetInsider | Truist Securities Reiterates Hold Rating on Arvinas Inc. (ARVN) amid positive Parkinson's data |
| February 24, 2026 7:02 pm | — | Wedbush | $11.00 | $12.37 | TheFly | Arvinas price target raised to $11 from $9 at Wedbush |
| December 17, 2025 10:54 am | — | Barclays | $18.00 | $11.90 | TheFly | Arvinas price target raised to $18 from $16 at Barclays |
| October 30, 2025 10:05 am | Jeet Mukherjee | BTIG | $14.00 | $9.59 | StreetInsider | Arvinas Inc. (ARVN) PT Raised to $14 at BTIG |
| October 15, 2025 8:47 am | — | Goldman Sachs | $6.00 | $9.41 | TheFly | Arvinas downgraded to Sell from Neutral at Goldman Sachs |
| October 7, 2025 12:54 pm | — | Piper Sandler | $16.00 | $9.36 | TheFly | Arvinas price target raised to $16 from $14 at Piper Sandler |
| September 18, 2025 1:49 pm | — | BTIG | $10.00 | $7.92 | TheFly | Arvinas price target lowered to $10 from $16 at BTIG |
| September 18, 2025 10:43 am | Sudan Loganathan | Stephens | $14.00 | $7.75 | TheFly | Arvinas price target lowered to $14 from $16 at Stephens |
| September 16, 2025 8:45 pm | — | Barclays | $16.00 | $7.64 | TheFly | Arvinas assumed with an Overweight at Barclays |
| June 2, 2025 3:44 pm | Andrew Fein | H.C. Wainwright | $24.00 | $7.33 | TheFly | Arvinas-Pfizer partnership dynamics may shift, says H.C. Wainwright |
Latest News for ARVN
JPMorgan Chase and Co. lifted its holdings in Arvinas, Inc. (NASDAQ: ARVN) by 475.5% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 214,779 shares of the company's stock after buying an additional 177,460 shares during the period. JPMorgan Chase
Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy –
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease –
Arvinas (NASDAQ: ARVN) executives outlined a portfolio shift toward early-stage development and previewed multiple clinical catalysts in a discussion hosted by Barclays biotech analyst Esra Darroudi. Chief Executive Officer Randy Teel and Chief Scientific Officer Angela Cacace said the company is entering 2026 with four Phase 1 programs and expects clinical data for three of those
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARVN.
U.S. House Trading
No House trades found for ARVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.